Log in to search using one of your social media accounts:

This page shows you the latest items in this publication.

European Commission Approves AMGEVITA ™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
First Biosimilar Adalimumab Approved in the European Union THOUSAND OAKS, Calif., March 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-severe hi...
Source: Amgen News Release - March 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients
Results From Two Studies Show Approximately 80 Percent of Prescription Claims in the U.S. Are Initially Rejected No Major Differences in Patient Characteristics Between Those Approved and Those Denied Access to a PCSK9 Therapy by Payers Data Presented at ACC.17 Provide Further Insights Into Patient Barriers for Accessing PCSK9 Inhibitors THOUSAND OAKS, Calif., March 19, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from two studies that showed that for appropriate patients (on-label) in the U.S., the majority of prescription claims for PCSK9 inhibitors, such as Repatha® (evolocumab), were in...
Source: Amgen News Release - March 19, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Lowering LDL Levels With Repatha ® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study
Repatha Cognitive Function Trial Evaluated Subset of Patients From Cardiovascular Outcomes Trial No Signal for Worsening Cognitive Function Observed Even in Patients Who Reached LDL Cholesterol Below 25 mg/dL Detailed Results From One of the Largest Randomized, Controlled Studies of Cognitive Function Presented at a Late-Breaking Clinical Trials Session at ACC.17 THOUSAND OAKS, Calif., March 18, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in the ...
Source: Amgen News Release - March 18, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Landmark Outcomes Study Shows That Repatha ® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent Risks of Heart Attack, Stroke and Coronary Revascularization Were Nominally Reduced by 27 Percent, 21 Percent and 22 Percent, Respectively Patients in Study had History of Heart Attack, Stroke or Symptomatic Peripheral Arterial Disease and Were Treated With Optimized Statin Therapy Amgen to Offer Innovative Refund Contracts in the U.S. Detailed Results Simultaneously Published in the New England Journal of Medicine and Presented at the American College of Cardiology 66th Annual Scientific Session THOUSAND OAKS, Calif.,...
Source: Amgen News Release - March 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Oppenheimer Global Health Care Conference
THOUSAND OAKS, Calif., March 16, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Oppenheimer Global Health Care Conference at 10:55 a.m. ET on Tuesday, March 21, 2017, in New York City. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, and David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the even...
Source: Amgen News Release - March 16, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Repatha ® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology'
Long-Term Study Identified No New Safety Concerns THOUSAND OAKS, Calif., March 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that four-year follow-up results from the Repatha® (evolocumab) OSLER-1 study, the longest PCSK9 inhibitor clinical trial to date, were published in JAMA Cardiology. Repatha, when added to standard of care (SOC), achieved median low-density lipoprotein cholesterol (LDL-C) reductions of 57 percent at four years, with no new safety concerns identified and no neutralizing antibodies observed with cumulative exposure.1 "For patients with cardiovascular disease, persistent LDL-C r...
Source: Amgen News Release - March 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Webcast Investor Meeting At Upcoming American College Of Cardiology Scientific Sessions
Late-Breaking Repatha® (Evolocumab) Presentations Will be Webcast Live at ACC.17 THOUSAND OAKS, Calif., March 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American College of Cardiology (ACC.17) Scientific Sessions on Friday, March 17, 2017, at noon ET. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss Amgen's cardiovascular program and data presented at ACC.17, including the Repatha® (evolocumab) cardiov...
Source: Amgen News Release - March 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Repatha ® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study
Study Meets Primary and All Secondary Endpoints THOUSAND OAKS, Calif., March 13, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from a Phase 3 study evaluating Repatha® (evolocumab) in patients who were receiving apheresis to reduce low-density lipoprotein cholesterol (LDL-C). The study met its primary endpoint, demonstrating that treatment with Repatha significantly reduced the need for LDL-C apheresis in adult patients, as measured at the end of the randomized period. The study also met its secondary endpoints of percent change from baseline to week 4 in LDL-C, non-high-density...
Source: Amgen News Release - March 13, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces 2017 Second Quarter Dividend
THOUSAND OAKS, Calif., March 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.15 per share dividend for the second quarter of 2017. The dividend will be paid on June 8, 2017, to all stockholders of record as of the close of business on May 17, 2017. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand...
Source: Amgen News Release - March 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Highlights Landmark Repatha ® (Evolocumab) Cardiovascular Outcomes Study Amongst Data To Be Presented At ACC.17
Additional Presentations Include an Assessment of Repatha's Effect on Cognitive Function and Challenges Associated With Access to PCSK9 Inhibitor Therapy Late-Breaking Repatha Presentations Will be Webcast Live THOUSAND OAKS, Calif., March 6, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that detailed results of the Repatha® (evolocumab) cardiovascular outcomes trial will be presented, as well as new data from across the cardiovascular portfolio, at the American College of Cardiology 66th Annual Scientific Session (ACC.17) in Washington, D.C., March 17-19, 2017. Detailed results from the Repatha card...
Source: Amgen News Release - March 6, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents New Data From Phase 3 XGEVA ® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop
In this study, XGEVA® (denosumab) met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.... (Source: Amgen News Release)
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents Overall Survival Data From KYPROLIS ® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop
Late-Breaking Presentation to Show Overall Survival Benefit of KYPROLIS Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival THOUSAND OAKS, Calif., March 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treat...
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Cowen And Company 37th Annual Health Care Conference
THOUSAND OAKS, Calif., March 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 37th Annual Health Care Conference at 11:20 a.m. ET on Wednesday, March 8, 2017, in Boston. Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, and David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the...
Source: Amgen News Release - March 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

BLINCYTO ® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
BLINCYTO Almost Doubled Median Overall Survival in High-Risk Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared to Standard of Care Chemotherapy BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy to Demonstrate Overall Survival Benefit in Patients With Philadelphia Chromosome-Negative Relapsed or Refractory Acute Lymphoblastic Leukemia Results Published in The New England Journal of Medicine THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the New England Journal of Medicine published results from the Phase 3 ...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New KYPROLIS ® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop
Detailed Results From Phase 3 Head-to-Head ENDEAVOR Trial Show KYPROLIS Significantly Improved Overall Survival Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients Late-Breaking Results From Largest International Trial Conducted in Multiple Myeloma Show XGEVA was Non-Inferior Versus Zoledronic Acid in Delaying Bone Complications THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the KYPROLIS® (carfilzomib) and XGEVA® (denosumab) clinical development programs will be presented at the 16th International Myeloma Workshop (IMW...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Phase 3 Head-to-Head Trial Showed KYPROLIS ® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients
First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival Detailed Results Will be Presented at the 16th International Myeloma Workshop (IMW) in New Delhi THOUSAND OAKS, Calif., Feb. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treated with KYPROLIS® (carfilzomib) and dexamethasone (Kd) lived ...
Source: Amgen News Release - February 28, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Repatha ® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Approval of the Automated Mini-Doser Marks First Hands-Free Administration Option for a PCSK9 Inhibitor in Europe THOUSAND OAKS, Calif., Feb. 21, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has adopted a decision to change the Repatha® (evolocumab) marketing authorization, approving a new single-dose delivery option. The new automated mini-doser (AMD) with a pre-filled cartridge is a hands-free device that provides 420 mg of Repatha in a single injection per administration. Repatha is the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Europe wi...
Source: Amgen News Release - February 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Submits Supplemental Biologics License Application For BLINCYTO ® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval Additional Data Support Treatment of Patients With Philadelphia Chromosome-Positive Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia BLINCYTO is the First Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Antibody and First Immunotherapy to Demonstrate Overall Survival Benefit Versus Standard of Care Chemotherapy THOUSAND OAKS, Calif., Feb. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License A...
Source: Amgen News Release - February 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Amgen's Parsabiv ™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Intravenous Administration Puts Delivery in Hands of Healthcare Provider THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first therapy approved for this condition in 12 years and the only calcimimetic that can be administered intravenously by the dialysis health care team three times a week at the end of the hemodialysis session. To view the ...
Source: Amgen News Release - February 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors
THOUSAND OAKS, Calif., Feb. 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Charles M. Holley Jr. to the Amgen Board of Directors. Mr. Holley will serve as a member of the Audit Committee and the Corporate Responsibility and Compliance Committee of the Board. Following the appointment of Mr. Holley, the Board will comprise 15 directors, 14 of whom are independent. "Charles Holley brings deep financial and organizational experience from one of the world's largest and most successful companies," said Robert A. Bradway, chairman and chief executive officer of Amgen. "We welcome Charles to Am...
Source: Amgen News Release - February 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2016. Key results include: For the fourth quarter, total revenues increased 8 percent versus the fourth quarter of 2015 to $6.0 billion. Product sales grew 6 percent driven by Enbrel® (etanercept), Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib). For the full year, total revenues increased 6 percent to $23.0 billion, with 5 percent product sales growth. GAAP earnings per share (EPS) increased 9 percent in the fourth quarter to $2.59...
Source: Amgen News Release - February 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Repatha ® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Landmark Repatha Cardiovascular Outcomes Study Meets Primary and Key Secondary Endpoint Detailed Results to be Presented at ACC 66th Annual Scientific Session THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and ...
Source: Amgen News Release - February 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Webcast of 2016 Fourth Quarter and Full Year Financial Results
THOUSAND OAKS, Calif., Jan. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2016 financial results on Thursday, Feb. 2, 2017, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news med...
Source: Amgen News Release - January 30, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
First Adalimumab Biosimilar Candidate Recommended for EMA Approval THOUSAND OAKS, Calif., Jan. 27, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 501 (biosimilar adalimumab), recommending approval for all available indications. ABP 501 has been recommended for approval for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis (AS), se...
Source: Amgen News Release - January 27, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv ™ (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
THOUSAND OAKS, Calif., Jan. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Journal of the American Medical Association (JAMA) publication of findings from three Phase 3 studies of Parsabiv™ (etelcalcetide), an investigational intravenous calcimimetic agent in the U.S. The studies evaluated Parsabiv in more than 1,700 adults with secondary hyperparathyroidism (sHPT) on hemodialysis and showed that the drug produced statistically significant and clinically meaningful reductions in serum parathyroid hormone (PTH) levels, a key marker of sHPT. sHPT is a chronic and serious condition that is often progressi...
Source: Amgen News Release - January 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Statement on January 9, 2017, U.S. District Court Decision
THOUSAND OAKS, Calif., Jan. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) issued the following statement regarding the U.S. District Court of Delaware's denial of Sanofi and Regeneron's motion to stay the injunction pending the appeal in the ongoing PCSK9 patent litigation: Today, the U.S. District Court of Delaware denied Sanofi and Regeneron's motion to stay the injunction pending the appeal in the ongoing PCSK9 patent litigation. By this ruling, the Court has extended the time before the injunction will be imposed by 15 days (from 30 days to 45 days) to allow Sanofi and Regeneron to seek appellate review of the Court'...
Source: Amgen News Release - January 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And DaVita Enter Into New Sourcing And Supply Agreement
THOUSAND OAKS, Calif., Jan. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it has entered into a six-year Sourcing and Supply Agreement with DaVita Inc.  This is a continuation of Amgen's long-term relationship with DaVita that is focused on serving dialysis patients. Under the terms of the new agreement, Amgen will supply DaVita with EPOGEN® (epoetin alfa) and Aranesp® (darbepoetin alfa) in amounts necessary to meet a specified annual percentage of DaVita's and its affiliates' requirements for erythropoiesis-stimulating agents used in providing dialysis services in the United States and Puerto Rico. The...
Source: Amgen News Release - January 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Arrangement Combines Immatics' XPRESIDENT® Technology and Amgen's Proprietary Bispecific Antibody Platform Immatics to Receive $30 Million Upfront and Potentially Over $1 Billion in Milestone Payments Plus Royalties THOUSAND OAKS, Calif. and TUEBINGEN, Germany, Jan. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, today announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers. The collaboration will combine Immatics'...
Source: Amgen News Release - January 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Court Grants Permanent Injunction For Infringement Of Amgen's Repatha ® Patents
THOUSAND OAKS, Calif., Jan. 5, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the United States District Court in Delaware granted Amgen's request for a permanent injunction prohibiting Sanofi and Regeneron from infringing two patents that Amgen holds for Repatha® (evolocumab) by manufacturing, using, selling or offering alirocumab for sale in the United States. The injunction will not take effect immediately as the court has delayed its imposition for 30 days to allow defendants the opportunity to seek expedited review of this decision. The judge's decision follows a jury verdict in March 2016 in Amge...
Source: Amgen News Release - January 6, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The 35th Annual J.P. Morgan Healthcare Conference
THOUSAND OAKS, Calif., Jan. 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 35th Annual J.P. Morgan Healthcare Conference at 2 p.m. PT on Monday, Jan. 9, 2017, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from seriou...
Source: Amgen News Release - January 4, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces 15 Percent Increase In 2017 First Quarter Dividend
THOUSAND OAKS, Calif., Dec. 20, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.15 per share dividend for the first quarter of 2017. The dividend will be paid on March 8, 2017, to all stockholders of record as of the close of business on Feb. 15, 2017. This represents a 15 percent increase from that paid in each of the previous four quarters. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by usin...
Source: Amgen News Release - December 20, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan
Phase 3 Data in Women and Men With Osteoporosis (From FRAME and BRIDGE Studies) Included in Marketing Application Romosozumab in Japan Being Co-Developed Through Key Strategic Alliance With Amgen Astellas BioPharma (AABP) THOUSAND OAKS, Calif. and BRUSSELS, Dec. 19, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that an application seeking marketing approval of romosozumab for the treatment of osteoporosis for those at high risk of fracture has been submitted for review to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Amgen and UCB are co-developing romos...
Source: Amgen News Release - December 20, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New Repatha ® (evolocumab) Dose Delivery Option Receives Positive CHMP Opinion
Allows for Administration of a 420 mg Dose in a Single Injection THOUSAND OAKS, Calif., Dec. 16, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for an extension to the marketing authorization of a new 420 mg single-dose delivery option for Repatha® (evolocumab). The new automated mini doser (AMD) with prefilled cartridge is a hands-free device designed to provide 420 mg of Repatha in a single injection per administration. Repatha is a human monoclonal antibody that blocks a pr...
Source: Amgen News Release - December 16, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Launch Of Blood Counts ™ And Collaboration With StoryCorps To Record And Share Stories Of Those Impacted By Multiple Myeloma
Through Sharing of Stories, Program Brings Awareness to Progress Made in Treating Multiple Myeloma Campaign Kicks off at 58th ASH Annual Meeting & Exposition With Recordings at StoryCorps MobileBooth in San Diego THOUSAND OAKS, Calif., Dec. 2, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of Blood Counts™, a national campaign dedicated to raising awareness of multiple myeloma and the importance of continued research to further advancements in treating this incurable blood cancer. As part of Blood Counts, Amgen will work with StoryCorps to record and share first-hand accounts from patien...
Source: Amgen News Release - December 2, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab
Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer THOUSAND OAKS, Calif., Dec. 2, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab). The companies believe this submission is the first bevacizumab biosimilar application submitted to the EMA. "The submission of ABP 215 to the EMA is an important milestone as Amgen seeks to expand our oncology portfolio," said Sean E. Harper, M.D., execut...
Source: Amgen News Release - December 2, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Citi 2016 Global Healthcare Conference
THOUSAND OAKS, Calif., Dec. 1, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Citi 2016 Global Healthcare Conference at 10:15 a.m. ET on Wednesday, Dec. 7, 2016, in New York City. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking the potential of biology for patients s...
Source: Amgen News Release - December 1, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Cytokinetics, Inc. (NASDAQ:CYTK) today announced The Lancet published results from a Phase 2 clinical trial evaluating omecamtiv mecarbil in patients with chronic heart failure. The COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) trial met its primary pharmacokinetic objective and showed statistically significant improvements in all pre-specified secondary measures of cardiac function in the treatment group receiving pharmacokinetic-based dose titration. The results wer...
Source: Amgen News Release - November 30, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016
Sub-Analysis From Phase 3 TOWER Study Compares Health-Related Quality of Life of BLINCYTO® (Blinatumomab) to Standard of Care Chemotherapy Analysis of Phase 3 Data Evaluates Cost-Effectiveness of KYPROLIS® (Carfilzomib) in Combination With Dexamethasone for Relapsed Multiple Myeloma Patients Long-Term Data Provide Insights on Safety and Efficacy of Nplate® (Romiplostim) in Children With Immune Thrombocytopenia THOUSAND OAKS, Calif., Nov. 30, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data will be presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH), ...
Source: Amgen News Release - November 30, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study
STRIVE Study Met its Primary Endpoint, Adding to Body of Episodic Migraine Prevention Data Migraine Ranked one of the Most Debilitating Diseases by the World Health Organization Erenumab Co-Developed by Amgen and Novartis THOUSAND OAKS, Calif., Nov. 16, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive top-line results for erenumab from a global Phase 3, randomized, double-blind, placebo-controlled STudy to evaluate the efficacy and safety of erenumab in migRaIne preVEntion (STRIVE). These data showed the STRIVE study met the primary endpoint, demonstrating statistically significant reductions from...
Source: Amgen News Release - November 16, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration
Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer THOUSAND OAKS, Calif., Nov. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab). ABP 215 is the most advanced of the four oncology biosimilar medicines that Amgen and Allergan are collaborating on. The companies believe this submission is the first bevacizumab biosimilar application submitted to the FDA. "ABP 215 is one of four onco...
Source: Amgen News Release - November 15, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news